Results from a biomarker study using clinical specimens collected from the ITN RAVE study (comparing Rituximab with cyclophosphamide in ANCA-associated Vasculitis (AAV); results here) were recently published in Arthritis and Rheumatism. AAV is a chronic disease that can be controlled with immunosuppression, but long-term management is challenging, flares are common and unpredictable, and generic inflammatory markers (proteinase 3 ANCA titers, erythrocyte sedimentation rate, C reactive protein, etc.) are unreliable predictors of disease ou